Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients - British Journal of Cancer
- ️Talieri, M
- ️Tue May 29 2001
Ardavanis A, Scorilas A, Amanatidou A, Gerakini F, Missitzis I, Garoufali A, Pissakas G, Pateras C, Apostolikas N, Rigatos G and Yiotis I (1997) Cathepsin-D concentration in tumour cytosols improves the accuracy of prognostic evaluation of primary breast cancer. Anticancer Res 17: 1405–1410
Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen Skobe M, Fusenig NE, Carmeliet P, Collen D and Foidart JM (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 8: 923–928
Benaud CH, Dickson RB and Thompson EW (1998) Roles of the matrix metalloproteinases in mammary gland development and cancer. Br Cancer Res Treat 50: 97–116
Bianchi E, Cohen RL, Dai A, Thor AT, Shuman MA and Smith HS (1995) Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer 60: 597–603
Blavier L and DeClerck YA (1997) Tissue inhibitor of metalloproteinases-2 is expressed in the interstitial matrix in adult mouse organs and during embryonic development. Molecular Biology of the Cell 8: 1513–1527
Bruner KL, Rodgers WH, Gold LI, Korc M, Hargrove JT, Matrisian LM and Osteen KG (1995) Transforming growth factor-b mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium. Proc Natl Acad Sci USA 92: 7362–7366
Chambers AF and Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260–1270
Daidone MG, Silverstrini R, D'Errico A, Di Fronza G, Benini E, Mancini A, Garbisa S Liotta L and Grigioni W (1991) Laminin receptors, collagenase IV and prognosis in node negative breast cancers. Int J Cancer 48: 529–532
Dano K, Behrendt N, Brunner N, Ellis V, Plong M and Pyke C (1994) The urokinase receptor: protein structure and the role in plasminogen activation and cancer invasion. Fibrinolysis 8: 189–203
Doussal VL, Tubiana-Hulin M, Friedman S, Hacerne K, Spyratos F and Brunet M (1989) Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR): an improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64: 1914–1922
Duffy MJ, Blaser J, Duggan C, McDermott E, O'Higgins N, Fennelly JJ and Tschesche H (1995) Assay of matrix metalloproteinases types 8 and 9 by ELISA in human breast cancer. Br J Cancer 71: 1025–1028
Elashry-Stowers D, Zava D, Speers W and Edwards D (1988) Immunochytochemical localization of progesterone receptors in breast cancer with antihuman receptor monoclonal antibodies. Cancer Res 48: 6462–6474
Friedman R, Toth M and Pena D Mobashery (1995) Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 55: 2548–2555
Garbett EA, Reed MWR and Brown NJ (1999) Proteolysis in human breast and colorectal cancer. Br J Cancer 81: 287–293
Hanemaaijer R, Sier C, Visser H, Scholte L, van Lent N, Toet K, Hoekman K and Verheijen J (1999) MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay modified urokinase as a substrate. Ann NY Acad Sci 878: 141–149
Heppner K, Matrisian L, Jensen R and Rodgers W (1996) Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 149: 273–282
Hewitt RE and Dano K (1996) Stromal cell expression of components of matrix degrading protease systems in human cancer. Enzyme Protein 49: 163–173
Jonat C, Rahmsdort HJ, Park K, Cato ACB, Gebel S, Ponta H and Herrlich P (1990) Anti-tumor promotion and anti-inflammation: down-modulation of AP-I (Fos/Jun) activity by glycocorticoid hormone. Cell 62: 1189–1204
Jones J, Glynn P and Walker R (1999) Expression of MMP-2 and MMP-9, their inhibitors and the activator MT1-MMP in primary breast carcinomas. J Pathol 189: 161–168
Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Karameris A, Panagou P, Tsilalis T and Bouros D (1997) Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study. Am J Respir Crit Care Med 156: 1930–1936
Kute TE, Hushe MS and Phyme AC (1980) Improvements in steroid receptor assays including rapid computer analysis of data. Anal Biochem 103: 272–279
Liotta LA and Stetler-Steverson G (1991) Tumor invasion and metastasis: An imbalance of positive and negative regulation. Cancer Res 51: 5054–5059
Magklara A, Scorilas A, Stephan C, Kristiansen G, Hauptmann S, Jung K and Diamandis EP (2000) Down-regulation of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) in malignant vs non-malignant prostatic tissue. Urology 56: 527–532
Mira E, Manes S, Lacalle RA, Marquer G and Mortinez C (1999) Insulin-like growth factor-1 triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology 140: 1657–1664
Nelson A, Fingleton B, Rothenberg M and Matrisian L (2000) Matrix metalloproteinase: Biologic activity and clinical implications. J Clin Oncol 18: 1135–1149
Nielsen BS, Timshel S, Kjeldsen L, Sehested Pyke C, Borregaard N and Dano K (1996a) 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 65: 57–62
Nielsen BS, Sehesed M, Timshel S, Pyke C and Dano K (1996b) Messenger RNA for urokinase plasminogen activator (uPA) is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Investigations 74: 168–177
Nielsen BS, Sehested M, Kjeldsen L, Borregaard N, Rygaard J and Danon K (1997) Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab Investigation 77: 345–355
Pacheco MM, Mourao M, Edson BM, Nishimoto IN and Brentani MM (1998) Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis 16: 577–585
Ree AH, Bjørnland K, Brünner N, Johansen HT, Pedersen KB, Aasen AO and Fodstad O (1998) Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells. Clin Exp Metastasis 16: 205–215
Remacle AG, Noël A, Duggan C, McDermott E, O'Higgins N, Foidart JM and Duffy MJ (1998) Assay of matrix metalloproteinases types 1,2,3 and 9 in breast cancer. Br J Cancer 77: 926–931
Rha SY, Kim JH, Roh JK, Lee KS, Min JS, Kim BS and Chung HC (1997) Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. Br Cancer Res Treatment 43: 175–181
Rha SY, Yang WI, Kim JH, Roh JK, Min JS, Lee KS, Kim BS and Chung HC (1998) Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncol Rep 5: 875–879
Salamonsen LA, Butt AR, Hammond R, Garcia S and Zhang J (1997) Production of endometrial matrix metalloproteinases, but not their tissue inhibitors are modulated by progesterone withdrawal in an in vitro model for menstruation. J Clin Endocrinol Metab 78: 1409–1415
Scorilas A, Yotis J, Gouriotis D, Keramopoulos A, Ampela K, Trangas T and Talieri M (1993) Cathepsin-D and c-erbB-2 have an additive prognostic value for breast cancer patients. Anticancer Res 13: 1895–1900
Scorilas A, Yotis J, Stravolemos K, Gouriotis D, Keramopoulos A, Ampela K, Talieri M and Trangas T (1995) c-erB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. Anticancer Res 15: 1543–1548
Scorilas A, Yotis J, Pateras CH, Trangas TH and Talieri M (1999a) Predictive value of c-erbB-2 and Cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. Clin Cancer Res 5: 815–821
Scorilas A, Trangas TH, Yotis J, Pateras CH and Talieri M (1999b) Determination of c-myc amplifications and overexpression in breast cancer patients. Evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathologic characteristics using univariate and multivariate analysis. Br J Cancer 81: 1385–1391
Scorilas A, Diamandis E, Levesque M, Papanastasiou-Diamandis A, Khoszavi M, Giai M, Ponzone R, Roagua R, Sismondi P and López-Otin C (1999c) Immuno-enzymatically determined pepsinogen C concentration in breast tumor cytosols: An independent favorable prognostic factor in node-positive patients. Clin Cancer Res 5: 1778–1785
Scorilas A, Talieri M, Ardavanis A, Courtis N, Yotis J, Dimitriadis E, Tsiapalis C and Trangas T (2000a) Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer. Cancer Res 60: 5427–5433
Scorilas A, Black M, Talieri M and Diamandis E (2000b) Genomic organization, physical mapping and expression analysis of the human protein arginine methyltransferase 1 gene. Biochem Biophys Res Commun 278: 349–359
Spiessl B, Beahrs OH, Hermanek P, Hutter RVP, Scheibe O, Sobin LH and Wagner G (1989) Illustrated guide to the TNM/p TNM classification of malignant tumours. TNM Atlas, 3rd edn
Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA and Goldberg GI (1995) Mechanisms of cell surface activation of 72-kDa type IV collagenase. J Biol Chem 270: 1–8
Sugiura Y, Shimada H, Seeger R, Lang W and Declerck YA (1998) Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: Contribution of stromal cells to their production and correlation with metastasis. Cancer Res 58: 2209–2216
Takeha S, Fujiyama Y, Bamda T, Sorsa T, Nagura H and Ohtani H (1997) Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: A novel approach from immune/inflammatory aspect. Jpn J Cancer 88: 72–81
Thorpe SM, Christensen IJ, Rasmussen BB and Rose C (1993) Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal primary breast cancer. Eur J Cancer 29A: 971–977
Tryggvason K, Hoyhtya M and Pyke C (1993) Type IV collagenase in invasive tumors. Br Cancer Res Treat 24: 209–218
Visscher DW, Hoyhtya M, Ottosen SK, Liang C-M, Sarkar FH, Crissman JD and Fridman R (1994) Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 59: 339–344
Vizoso F, Sanchez LM, Diez-Itza I, Merino AM and Lopez-Otin C (1995) Pepsinogen C is a new prognostic marker in primary breast cancer. J Clin Oncol 13: 54–61
Vu TH and Werb Z (1998) Gelatinase B Structure, regulation and function. In: Matrix metalloproteinases, Parks W C Mecham R P (eds) pp 115–148. Academic Press: San Diego, CA
Yan S, Sameni M and Sloane BF (1998) Cathepsin B and human tumor progression. Biol Chem 379: 113–123
Yousef GM, Scorilas A and Diamandis EP (2000) Genomic organization, mapping, tissue expression and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. Genomics 63: 88–96
Yousef G, Scorilas A, Jung K, Aschworth L and Diamandis EP (2001) The new human kallikrein gene KLK15 is up-regulated in prostate cancer. J Biol Chem 276: 53–61
Yu H, Levesque MA, Clark GM and Diamandis EP (1998) Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res 4: 1489–1497
Yu Q and Stamenkovic (1999) Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invation. Genes Dev 13: 35–48
Zucker S, Hymowitz M, Conner C, Zarrabi H, Hurewitz A, Matrisian L, Boyd D, Nicolson G and Montana S (1999) Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Ann NY Acad Sci 878: 212–227